NecroX-7
NecroX-7 is a potent free radical scavenger and a HMGB1 (high-mobility group box 1) inhibitor. NecroX-7 can be used as an antidote to acetaminophen toxicity. NecroX-7 exerts a protective effect by preventing the release of HMGB1 in ischemia/reperfusion injury. NecroX-7 inhibits the HMGB1-induced release of TNF and IL-6, as well as the expression of TLR-4 and receptor for advanced glycation end products. NecroX-7 can be used graft-versus-host disease (GVHD) research[1].
Product Specifications
CAS Number
1120332-55-9
UNSPSC
12352005
Target
Interleukin Related; Reactive Oxygen Species (ROS) ; TNF Receptor; Toll-like Receptor (TLR)
Type
Reference compound
Related Pathways
Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/necrox-7.html
Purity
99.69
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=S1(CCN(CC1)CC2=CC3=C(C(NC4CCOCC4)=C2)NC(C5=CC=CC=C5)=C3)=O
Molecular Formula
C24H29N3O3S
Molecular Weight
439.57
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
IL-6; TLR4
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
OR2B3 sgRNA CRISPR Lentivector (Human) (Target 3)
Serpinb6b sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 2)
Recombinant Schizosaccharomyces pombe Uncharacterized TLC domain-containing protein C17A2.02c (SPAC17A2.02c), partial
